Use of bone turnover markers in clinical practice

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 6, 2012, Pages 468-473

  Biver, Emmanuel ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

bone turnover markers; fracture risk; osteoporosis; treatment monitoring

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; DEOXYPYRIDOLINE; IBANDRONIC ACID; OSTEOCALCIN; PROCOLLAGEN TYPE I AMINO TERMINAL PROPEPTIDE; PROCOLLAGEN TYPE I CARBOXY TERMINAL PROPEPTIDE; PYRIDOLINE; RALOXIFENE; RISEDRONIC ACID; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AUTOMATION; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CLINICAL PRACTICE; DIAGNOSTIC TEST ACCURACY STUDY; FOREARM FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LIFESTYLE; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SPINE FRACTURE; TREATMENT RESPONSE;

AGE FACTORS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; FEMALE; GUIDELINES AS TOPIC; HUMANS; LIFE STYLE; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PEPTIDES; REFERENCE STANDARDS; RISK ASSESSMENT; SEX FACTORS; TREATMENT OUTCOME;

EID: 84869768551     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283591492     Document Type: Review

References (41)

1. Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9:1137-1141.
2. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15:1526-1536.
3. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008; 12:157-170.
4. Garcia-Martin A, Cortes-Berdonces M, Luque-Fernandez I, et al. Osteocalcin as a marker of metabolic risk in healthy postmenopausal women. Menopause 2011; 18:537-541.
5. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22:391-420.
6. Jabbar S, Drury J, Fordham JN, et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol 2011; 64:354-357.
7. Garnero P, Sornay-Rendu E, Munoz F et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2012. [Epub ahead of print].
8. Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012; 8:379-389.
9. Lombardi G, Lanteri P, Colombini A, Banfi G. Blood biochemical markers of bone turnover: preanalytical and technical aspects of sample collection and handling. Clin Chem Lab Med 2012; 50:771-789.
10. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31:57-61.
11. Grados F, Brazier M, Kamel S, et al. Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 2003; 88:5175-5179.
12. Glover SJ, Garnero P, Naylor K, et al. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008; 42:623-630.
13. Adami S, Bianchi G, Brandi ML, et al. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 2008; 82:341-347.
14. Moghaddam A, Muller U, Roth HJ, et al. TRACP 5b and CTX as osteological markers of delayed fracture healing. Injury 2011; 42:758-764.
15. Eastell R, Garnero P, Audebert C, Cahall DL. Reference intervals of bone turnover markers in healthy premenopausal women: results from a crosssectional European study. Bone 2012; 50:1141-1147.
16. Rosenquist C, Fledelius C, Christgau S, et al. Serum cross laps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998; 44:2281-2289.
17. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001; 47:694-702.
18. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective Study. J Bone Miner Res 1996; 11:1531-1538.
19. Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009; 24:389-397.
20. Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009; 45:1053-1058.
21. Szulc P, Garnero P, Munoz F, et al. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001; 16:1642-1650.
22. Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine 2012; 79:20-25.
23. Chopin F, Biver E, Funck-Brentano T, et al. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis. Joint Bone Spine 2012; 79:26-31.
24. McCloskey EV, Vasikaran S, Cooper C. Official Positions for FRAX(R) clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J Clin Densitom 2011; 14:220-222.
25. Ivaska KK, Gerdhem P, Vaananen HK, et al. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010; 25:393-403.
26. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18:1051-1056.
27. Delmas PD, Licata AA, Reginster JY, et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006; 39:237-243.
28. Seibel MJ, Naganathan V, Barton I, Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004; 19:323-329.
29. Funck-Brentano T, Biver E, Chopin F, et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review. Semin Arthritis Rheum 2011; 41:157-169.
30. Eastell R, Rogers A, Ni X, Krege JH. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporos Int 2011; 22:1927-1934.
31. Eastell R, Hannon RA, Garnero P, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007; 22:1656-1660.
32. Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009; 24:1544-1551.
33. Eastell R, Vrijens B, Cahall DL, et al. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 2011; 26:1662-1669.
34. Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007; 40:1238-1243.
35. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011; 26:530-537.
36. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20:141-151.
37. Emkey R, Delmas PD, Bolognese M, et al. Efficacy and tolerability of oncemonthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther 2009; 31:751-761.
38. Eastell R, Walsh JS, Watts NB, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011; 49:82-88.
39. Quesada-Gomez JM, Muschitz C, Gomez-Reino J, et al. The effect of PTH (1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial. Osteoporos Int 2011; 22:2529-2537.
40. Kung AW, Rachman IA, Adam JM, et al. Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women. Int J Rheum Dis 2009; 12:216-224.
41. Eastell R, Krege JH, Chen P, et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006; 22:61-66.